Browsing by Autor "Elizabeth García"

Filter results by typing the first few letters
Now showing 1 - 5 of 5
  • Thumbnail Image
    Item type: Item ,
    Differences in Systemic and Skin Migrating-Specific CD4<sup>+</sup> T Cells in Papular Urticaria by Flea Bite
    (Karger Publishers, 2012) Omar Domínguez-Amorocho; Silvia Duarte; John Mario González; Evelyne Halpert; María Claudia Ortega; Adriana Rodríguez Ciódaro; Elizabeth García; Adriana Cuéllar
    Analysis of the cellular immune response against whole flea antigen in patients with papular urticaria by flea bites suggests a possible participation of inflammatory cytokines in the skin reaction (Th17) and a systemic control mechanism (IL-10). This pattern of cytokine production in patients could be a consequence of an impaired dendritic cell population.
  • Thumbnail Image
    Item type: Item ,
  • Thumbnail Image
    Item type: Item ,
    Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A series of cases
    (Colegio Mexicano de Inmunología Clínica y Alergia, A.C., 2019) María Alejandra García; Alejandro Durán Crane; Edgardo Chapman; Elizabeth García
    Omalizumab appears promising for treating severe atopic dermatitis in pediatric patients. That results shows that omalizubam improves the quality of life, also decreases the severity of the disease and the need for systemic steroid and immunosuppressive therapy, which decreases the side effects that are caused by these medications.
  • Thumbnail Image
    Item type: Item ,
    Omalizumab como terapia adyuvante para la dermatitis atópica severa en niños: una serie de casos
    (2018) María Alejandra García; Alejandro Durán; Edgardo Chapman; Elizabeth García
    Antecedentes: La dermatitis atópica es una enfermedad crónica de la piel que compromete la calidad de vida. El omalizumab, un anticuerpo monoclonal que bloquea IgE, puede ofrecer un beneficio para controlar dermatitis atópica severa en la población pediátrica. Objetivo: Describir la experiencia de un centro de alergología pediátrica con el uso de omalizumab para dermatitis atópica severa. Métodos: Se revisaron las historias clínicas de pacientes < 18 años de edad con dermatitis atópica severa en el Servicio de Alergología Pediátrica de la Fundación Santa Fe de Bogotá, Colombia, entre 2010 y el 2015. Se seleccionaron pacientes que recibieron omalizumab como terapia coadyuvante por lo menos seis meses. Se analizaron las características clínicas de base, la duración del tratamiento y tiempo hasta notar mejoría, severidad de la enfermedad con el SCORAD y compromiso en la calidad de vida con el CDLQI al final del tratamiento. Los análisis estadísticos se realizaron con STATA versión 12. Resultados: Se obtuvieron 19 pacientes. Al inicio todos reportaban compromiso severo de la calidad de vida, 17 habían recibido tratamiento con esteroides sistémicos y 12 habían recibido otro tipo de terapia de inmunosupresión sin control de los síntomas. Se obtuvieron puntuaciones de Scoring Atopic Dermatitis al tiempo máximo de tratamiento en 13 pacientes, 85.7 % de los cuales era consistente con enfermedad leve/moderada y 14.3 % con enfermedad severa. La mayoría de los pacientes mostró mejoría en su calidad de vida. En todos los pacientes se suspendió el corticoide sistémico, sin necesidad de reiniciarlo durante el tratamiento con omalizumab. Conclusiones: El omalizumab promete grandes beneficios como terapia coadyuvante para el manejo de la dermatitis atópica severa resistente en pacientes pediátricos. Su uso disminuye la severidad de la enfermedad, mejora la calidad de vida y disminuye el uso de inmunosupresores sistémicos evitando efectos adversos relacionados con el uso crónico de estos.
  • Thumbnail Image
    Item type: Item ,
    Prevalence of and factors associated with current asthma symptoms in school children aged 6–7 and 13–14 yr old in Bogotá, Colombia
    (Wiley, 2008) Elizabeth García; Gustavo Aristizábal; Catalina Vásquez; Carlos E. Rodríguez‐Martínez; Olga L. Sarmiento; Claudia L. Satizábal
    This cross‐sectional study of children aged 6–7 years and adolescents aged 13–14 years in Bogotá, Colombia, assessed the prevalence of asthma symptoms and their associations with dietary, health, and behavioral habits. This study is part of the International Study of Asthma and Allergies in Childhood (ISAAC)‐phase III. Asthma prevalence among the children was assessed using a parental self‐administered written questionnaire (WQ), and among adolescents using a WQ together with a video questionnaire (VQ). Associations were estimated with bivariate and multivariate analysis. The study found that the 6–7 year age‐group were more likely to report current asthma symptoms than the 13–14 year age‐group (10.4% [WQ] vs. 8.6% [WQ] and 8.0% [VQ], respectively). Factors associated with current asthma symptoms among the 6–7 year age‐group included higher maternal education (OR = 1.7, [95% CI 1.2–2.6], p = 0.007), a cat in the home during the last year (OR = 1.5, [95% CI 1.0–2.3], p = 0.036), watching TV 1–2 hours/day (OR = 2.1, [95% CI 1.2–3.9], p = 0.013), and medication with acetaminophen in the first and most recent year of life (OR = 1.8, [95% CI 1.3–2.4], p &lt; 0.001; OR = 2.2, [95% CI 1.7–2.8], p &lt; 0.001, respectively) or antibiotics in the first year of life (OR = 1.9, [95% CI 1.4–2.5], p &lt; 0.001). Among the 13–14 year age‐group, factors associated with current asthma symptoms included medication with acetaminophen during the last year (OR = 1.8, [95% CI 1.4–2.3], p &lt; 0.001); cereal, milk, and fruit consumption 3 or more times weekly (OR = 1.5, [95% CI 1.1–1.9], p = 0.010; OR = 0.8, [95% CI 0.6–1.0], p = 0.046; OR = 0.6, [95% CI 0.4–1.0], p = 0.031, respectively). Overall, compared with that in other Latin American centers, asthma prevalence in Bogotá is close the lower estimates. However, associations with dietary, health, and behavioral habits need further study to assess their complex relationship with asthma.